CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
by Answers in CME
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇨🇦CA · Life Sciences#1265K to 30K
- 🇸🇦SA · Life Sciences#116500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
2.8K to 17K🎙 ~2x weekly·41 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
5.5K to 33K🇨🇦91%🇸🇦9% - Active Followers
Loyal subscribers who consistently listen
2.2K to 13K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis
May 15, 2026
Unknown duration
From Burden to Breakthrough: The Rise of KIT D816V-Selective Therapy in Indolent Systemic Mastocytosis
May 5, 2026
Unknown duration
Early Defense: Answering Key Questions About the Science and Strategy of RSV Prevention in Infants
Apr 23, 2026
Unknown duration
Test, Treat, Repeat: Closing Persistent Gaps in HCV Care
Apr 8, 2026
Unknown duration
When Form Maximizes Function: Examining the Role of Subcutaneous Immune Checkpoint Inhibitors in Oncology Practice
Mar 24, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5/15/26 | KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis | Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis and care planning; Describe current and emerging treatment options for patients with AdvSM; and Evaluate patient- and disease-related strategies that inform treatment selection in AdvSM. | — | ||||||
| 5/5/26 | From Burden to Breakthrough: The Rise of KIT D816V-Selective Therapy in Indolent Systemic Mastocytosis | Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients’ quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM. | — | ||||||
| 4/23/26 | Early Defense: Answering Key Questions About the Science and Strategy of RSV Prevention in Infants | Please visit answersincme.com/FNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Karen P. Acker, MD. In this activity, an expert in microbiology and immunology discusses recommendations and strategies for enhancing the uptake of respiratory syncytial virus (RSV) immunization in infants. Upon completion of this activity, participants should be better able to: Recognize the rationale for respiratory syncytial virus (RSV) immunization in infants and children; Review guideline-recommended immunization strategies for RSV prevention in infants, including the benefits and limitations of maternal versus infant immunization approaches; and Formulate effective, patient-centered communication strategies to enhance the uptake of RSV immunization in infants. | — | ||||||
| 4/8/26 | Test, Treat, Repeat: Closing Persistent Gaps in HCV Care | Please visit answersincme.com/QSK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Markus Cornberg, MD. In this activity, an expert in infectious diseases discusses the management of patients with hepatitis C virus (HCV) infection. Upon completion of this activity, participants should be better able to: Discuss the factors influencing timely intervention in hepatitis C virus (HCV) management; Describe recommended HCV screening strategies to increase uptake in underserved populations; and Recognize appropriate criteria for initiating simplified HCV therapy or referring patients for specialist care. | — | ||||||
| 3/24/26 | When Form Maximizes Function: Examining the Role of Subcutaneous Immune Checkpoint Inhibitors in Oncology Practice | Please visit answersincme.com/KWA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Benjamin Levy, MD, FASCO. In this activity, an expert in oncology discusses the use of subcutaneous immune checkpoint inhibitors. Upon completion of this activity, participants should be better able to: Describe the rationale for subcutaneous (SC) immune checkpoint inhibitor (ICI) administration in the context of standard care with intravenous (IV) formulations in patients with advanced solid tumors; Review the evidence for SC formulations of ICIs compared with IV formulations in patients with advanced solid tumors; and Propose patient-centered strategies for enhancing care with SC administration of ICIs in patients with advanced solid tumors. | — | ||||||
| 3/13/26 | Precision Use of Biologic Therapies in Eosinophilic Lung Disease: Case-Based Strategies to Optimize Treatment Selection and Reduce Steroid Burden | Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the implications of real-world data on biologic therapies for addressing airway remodeling and airway plugging; Develop steroid-sparing treatment plans and monitoring strategies for patients with severe eosinophilic asthma; and Formulate treatment plans to adjust the use of biologic therapies in patients with severe eosinophilic asthma and overlapping eosinophilic comorbidities. | — | ||||||
| 2/18/26 | The Psoriatic Disease Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape | Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA. | — | ||||||
| 1/19/26 | Strategic Biologic Selection in Women of Childbearing Potential: Patient-Specific Approaches in Inflammatory Arthritis Care | Please visit answersincme.com/860/240201321-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Neda Amiri, MD, MHSc, FRCPC, ABIM; Dharini Mahendira, MD, FRCPC, MScCH and Eleftherios Soleas, PhD. In this activity, experts in rheumatology discuss evidence-based strategies to facilitate the selection and optimization of biologic therapies in women with inflammatory arthritis who are of childbearing potential. Upon completion of this activity, participants should be better able to: Describe how patient-specific factors, including fertility status, pregnancy, and lactation, inform personalized biological therapy selection in inflammatory arthritis; Evaluate the efficacy and safety profiles of approved biologics in women of childbearing potential across inflammatory arthritis indications; and Apply strategies to optimize management decisions in reproductive-age women with inflammatory arthritis. | — | ||||||
| 12/30/25 | Tina Q. Tan, MD - Infant RSV Protection: Guiding Families Through Immunization Decisions in Clinical Practice | Please visit answersincme.com/WFH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in infectious diseases discusses RSV vaccination indications, scheduling, and uptake. Upon completion of this activity, participants should be better able to: Identify the pressing need for RSV prevention in infants (≤24 months); Compare the administration schedules and clinical indications of available RSV prophylactic agents for infants; and Review strategies to address caregiver concerns and increase uptake of RSV prophylaxis in infants. | — | ||||||
| 12/24/25 | Karen McAssey, BA, MD, M.Ed, FRCPC - Frail Bones, Strong Impact: Mending Gaps in Hypophosphatasia Recognition Across Canada | Please visit answersincme.com/RND860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hypophosphatasia (HPP) discuss its multisystem burden and diagnostic challenges, and the importance of early referral for timely treatment. Upon completion of this activity, participants should be better able to: Describe the clinical burden and multisystem manifestations of HPP across the lifespan; Recognize key diagnostic challenges in HPP through practical screening strategies, including interpretation of alkaline phosphatase (ALP) and pyridoxal 5′-phosphate (PLP) levels; and Outline the importance of early referral and diagnostic confirmation to enable timely treatment initiation, including the role of genetic testing and family screening. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 12/17/25 | Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care | Please visit answersincme.com/NEH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA. | — | ||||||
| 12/16/25 | Samir V. Parikh, MD, FASN - Emerging Therapeutic Options for Lupus Nephritis: Preserving Kidney Function and Delaying Progression | Please visit answersincme.com/VTG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lupus nephritis (LN) discusses the latest evidence and guidance on using biologic therapies in this patient population. Upon completion of this activity, participants should be better able to: Discuss the rationale for adding a biologic agent to standard immunosuppressive therapy to improve outcomes in LN; Review the clinical evidence for available and emerging B-cell biologic agents in LN; and Identify patients with LN who are candidates to receive biologic add-on therapy. | — | ||||||
| 12/11/25 | Nicola Hanania, MD, MS / Surya P. Bhatt, MD, MSPH - Demystifying the Evidence for Biologics in COPD: Strategies for Optimized, Patient-Centered Management | Please visit answersincme.com/860/MED-RESP-03658-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in pulmonary medicine discuss how to integrate biologics into individualized treatment plans for chronic obstructive pulmonary disease (COPD), featuring insights from a patient advocate. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting eosinophilic inflammation in COPD; Differentiate available and late-stage emerging biologic therapies based on the latest clinical evidence in COPD; Identify patients with COPD who are appropriate candidates for biologic therapy; and Outline strategies to optimally incorporate biologic therapies into treatment plans for patients with COPD. | — | ||||||
| 12/10/25 | Sheilagh M. Maguiness, MD, FAAP / Elizabeth Vainder, MD, FAAP - Escalating Atopic Dermatitis Treatment in Pediatric Patients With Confidence: What Do the Guidelines Tell Us? | Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only. | — | ||||||
| 12/8/25 | Stella Lee, MD / Kathleen Buchheit, MD - Striving for Patient Satisfaction in the Present and Future: Personalizing Treatment in an Evolving Paradigm | Please visit answersincme.com/860/99066167-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in nasal polyps discuss personalizing treatment selection in CRSwNP with emerging biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available. | — | ||||||
| 11/27/25 | Stella Lee, MD / Joseph K. Han, MD, FARS, FAAAAI - Spotlight on Emerging Biologics: Interpreting the Latest Efficacy and Safety Signals | Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available. | — | ||||||
| 11/21/25 | Anne K. Ellis, MD, MSc, FRCPC / Andrew Thamboo, MD, FRCSC / Meyer Balter, MD, FRCPC - Advancing CRSwNP Care: Multidisciplinary Insights on Early Detection and the Role of Biologic Therapies | Please visit answersincme.com/PME860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) discuss strategies for optimizing the detection and management of CRSwNP, with a focus on the role of biologics in patient-centered care. Upon completion of this activity, participants should be better able to: Identify best practices to facilitate the early detection of CRSwNP; Discuss the risk-benefit profiles of approved and emerging biologics for the treatment of CRSwNP; and Identify patient-centered, multidisciplinary strategies to integrate biologics into the treatment algorithm for patients with CRSwNP. | — | ||||||
| 11/20/25 | Doreen Addrizzo-Harris, MD - Relieving the Weight of Non-Cystic Fibrosis Bronchiectasis: Updated Strategies for an Evolving Landscape | Please visit answersincme.com/KUS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary medicine discusses the treatment of patients with non–cystic fibrosis bronchiectasis (NCFB) using dipeptidyl peptidase 1 (DPP1) inhibitors. Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting neutrophilic inflammation in non–cystic fibrosis bronchiectasis (NCFB); Describe the clinical impact of DPP1 inhibitors for treating NCFB, in the context of conventional therapy; Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanomaApply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves; and Apply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves. | — | ||||||
| 11/18/25 | Stella Lee, MD / Kathleen Buchheit, MD - Advances in CRSwNP: Rethinking Biologics and Inflammation at the Source | Please visit answersincme.com/860/99066167-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the ongoing burden of CRSwNP and the rationale for exploring novel biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents. | — | ||||||
| 10/30/25 | Liam O'Neil, MD, MHSc - Rheumatoid Factor in Focus: Serologic Insights Driving Personalized Rheumatoid Arthritis Care | Please visit answersincme.com/KDN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rheumatology discusses the role of rheumatoid factor and other biomarkers in guiding personalized management in patients with rheumatoid arthritis. Upon completion of this activity, participants should be better able to: Recognize the relevance of rheumatoid factor (RF) as a prognostic biomarker in rheumatoid arthritis (RA); Discuss the efficacy and safety considerations of biologic therapies in RA, including the potential influence of RF titers; and Apply biomarker-driven strategies to personalize RA management across diverse patient populations. | — | ||||||
| 10/28/25 | Charles L. Daley, MD / David E. Griffith, MD - Staying on Track with MAC Lung Disease Care: From Accurate Diagnosis to Evolving Management Strategies | Please visit answersincme.com/860/96036801-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss the latest in diagnosis and optimized management of Mycobacterium avium complex (MAC) lung disease. Upon completion of this activity, participants should be better able to: Describe strategies to assess suspected nontuberculous mycobacterial (NTM) lung disease; Review guideline-recommended treatment plans for Mycobacterium avium complex (MAC) lung disease; Explain the clinical significance of the latest evidence for emerging first-line therapies for MAC lung disease, in the context of current standard of care; and Outline best practices to enhance outcomes for patients with MAC lung disease, including those receiving approved or emerging first-line therapies. | — | ||||||
| 10/17/25 | MeiLan Han, MD, MS / Eddie Needham, MD, FAAFP / Valerie Chang - COPD Primary Care Playbook: Boosting Diagnosis, Treatment, and Therapy Escalation for Optimal Disease Control | Please visit answersincme.com/860/MED-RESP-03268-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a family medicine physician and a pulmonologist discuss strategies for optimizing chronic obstructive pulmonary disease (COPD) detection and management in primary care. Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations on the management of COPD; Identify the impact of approved follow-up pharmacotherapies in the treatment of COPD; and Determine personalized strategies to incorporate follow-up pharmacotherapies into clinical practice for COPD. | — | ||||||
| 10/15/25 | Jerry P. Abraham, MD MPH CMQ / Chuck Vega, MD- Primary Care Immunization Showdown: What Would You Do in These Complex Vaccine Scenarios? | Please visit answersincme.com/860/CME-25-198904-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease and family medicine discuss complex immunization needs of all patients, especially those with altered immunocompetence. Upon completion of this activity, participants should be better able to: Review how having altered immunocompetence affects response to vaccines; Apply the national guideline recommendations for immunization in individuals with altered immunocompetence; and Formulate effective communication strategies to enhance vaccine uptake in individuals with altered immunocompetence. | — | ||||||
| 9/24/25 | Stephanie Christenson, MD, MAS - Beyond Standard Care: Enhancing Disease Control With Biologic Therapy for Eosinophilic COPD | Please visit answersincme.com/XVH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the role of biologic therapy in patients with eosinophilic chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify patients with unmet therapeutic needs despite guideline-recommended management of chronic obstructive pulmonary disease (COPD); Review the clinical rationale for approved and emerging biologics targeting type 2 inflammation in the treatment of eosinophilic COPD; and Assess strategies to incorporate biologics targeting type 2 inflammation into clinical practice for COPD, as they become available. | — | ||||||
| 9/9/25 | Tina Q. Tan, MD / Litjen (L.J) Tan, MS, PhD - Empowering Patients, Strengthening Immunity: Strategies to Increase Influenza Vaccination Across All Age Groups | Please visit answersincme.com/860/95719487-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in vaccine-preventable diseases discuss the most up-to-date evidence-based recommendations for flu vaccination, as well as strategies to enhance uptake across all age groups. Upon completion of this activity, participants should be better able to: Discuss the therapeutic rationale for seasonal influenza vaccination across all age groups; Describe the clinical profiles of recommended influenza vaccines; and Outline practical strategies to enhance influenza vaccination uptake across all age groups. | — | ||||||
Showing 25 of 44
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.